Elranatamab monotherapy in the real-word setting in relapsed-refractory multiple myeloma: results of the French compassionate use program on behalf of the IFM.
作者信息
Malard Florent, Bobin Arthur, Labopin Myriam, Karlin Lionel, Frenzel Laurent, Roussel Murielle, Vignon Marguerite, Godet Sophie, Chalopin Thomas, Moyer Perrine, Chalayer Emilie, Orsini Piocelle Frederique, Mariette Clara, Croizier Carolyne, Sohn Claudine, Dib Mamoun, Le Calloch Ronan, Ali-Ammar Nadia, Loirat Marion, Benbrahim Omar, Payssot Alexandre, Trebouet Adrien, Perrot Aurore, Leleu Xavier, Mohty Mohamad
机构信息
Sorbonne Université, Centre de Recherche Saint-Antoine INSERM UMRs938, Paris, France.
Service d'Hématologie Clinique et de Thérapie Cellulaire, Hôpital Saint Antoine, AP-HP, Paris, France.
出版信息
Blood Cancer J. 2024 Dec 18;14(1):219. doi: 10.1038/s41408-024-01200-w.
Abstract
摘要
相似文献
1
Elranatamab monotherapy in the real-word setting in relapsed-refractory multiple myeloma: results of the French compassionate use program on behalf of the IFM.
Blood Cancer J. 2024 Dec 18;14(1):219. doi: 10.1038/s41408-024-01200-w.
2
Elranatamab efficacy in MagnetisMM-3 compared with real-world control arms in triple-class refractory multiple myeloma.
Future Oncol. 2024;20(17):1175-1189. doi: 10.2217/fon-2023-0995. Epub 2024 Feb 28.
3
A tertiary care centre experience with Elranatamab: A report of three cases.
Leuk Res Rep. 2024 Jun 13;21:100466. doi: 10.1016/j.lrr.2024.100466. eCollection 2024.
4
Engaging a New Treatment Paradigm: Elranatamab in Relapsed/Refractory Multiple Myeloma.
Ann Pharmacother. 2025 May;59(5):473-484. doi: 10.1177/10600280241281742. Epub 2024 Oct 16.
5
6
Elranatamab in relapsed or refractory multiple myeloma: the MagnetisMM-1 phase 1 trial.
Nat Med. 2023 Oct;29(10):2570-2576. doi: 10.1038/s41591-023-02589-w. Epub 2023 Oct 2.
7
Economic Impact of Elranatamab for Treatment of Patients with Relapsed or Refractory Multiple Myeloma.
Clinicoecon Outcomes Res. 2025 Apr 8;17:289-302. doi: 10.2147/CEOR.S501404. eCollection 2025.
8
Elranatamab: First Approval.
Drugs. 2023 Nov;83(17):1621-1627. doi: 10.1007/s40265-023-01954-w.
9
Relapsed refractory multiple myeloma with CNS involvement successfully treated with Elranatamab: first reported case.
Front Immunol. 2023 Oct 13;14:1276295. doi: 10.3389/fimmu.2023.1276295. eCollection 2023.
10
Elranatamab in Japanese patients with relapsed/refractory multiple myeloma: results from MagnetisMM-2 and MagnetisMM-3.
Jpn J Clin Oncol. 2024 Sep 4;54(9):991-1000. doi: 10.1093/jjco/hyae068.
引用本文的文献
1
T cell redirecting therapy for relapsed multiple myeloma.
Discov Oncol. 2025 Aug 18;16(1):1573. doi: 10.1007/s12672-025-03432-z.
2
The Evolving Treatment Landscape for the Elderly Multiple Myeloma Patient: From Quad Regimens to T-Cell Engagers and CAR-T.
Cancers (Basel). 2025 Aug 5;17(15):2579. doi: 10.3390/cancers17152579.
3
MAMDC2-AS1 Induces Cuproptosis in Relapsed and Refractory Multiple Myeloma.
Cancer Rep (Hoboken). 2025 May;8(5):e70216. doi: 10.1002/cnr2.70216.
4
Elranatamab versus physician's choice of treatment in patients with triple-class exposed/refractory multiple myeloma: an updated matching-adjusted indirect comparison.
J Comp Eff Res. 2025 May;14(5):e240236. doi: 10.57264/cer-2024-0236. Epub 2025 Apr 7.
本文引用的文献
1
Multiple myeloma.
Nat Rev Dis Primers. 2024 Jun 27;10(1):45. doi: 10.1038/s41572-024-00529-7.
2
Teclistamab in relapsed refractory multiple myeloma: multi-institutional real-world study.
Blood Cancer J. 2024 Mar 5;14(1):35. doi: 10.1038/s41408-024-01003-z.
3
Real-world analysis of teclistamab in 123 RRMM patients from Germany.
Leukemia. 2024 Feb;38(2):365-371. doi: 10.1038/s41375-024-02154-5. Epub 2024 Jan 20.
4
Elranatamab in relapsed or refractory multiple myeloma: the MagnetisMM-1 phase 1 trial.
Nat Med. 2023 Oct;29(10):2570-2576. doi: 10.1038/s41591-023-02589-w. Epub 2023 Oct 2.
5
Elranatamab in relapsed or refractory multiple myeloma: phase 2 MagnetisMM-3 trial results.
Nat Med. 2023 Sep;29(9):2259-2267. doi: 10.1038/s41591-023-02528-9. Epub 2023 Aug 15.
6
Infections following bispecific antibodies in myeloma: a systematic review and meta-analysis.
Blood Adv. 2023 Oct 10;7(19):5898-5903. doi: 10.1182/bloodadvances.2023010539.
7
Impact of performance status on overall survival in patients with relapsed and/or refractory multiple myeloma: Real-life outcomes of daratumumab treatment.
Eur J Haematol. 2020 Aug;105(2):196-202. doi: 10.1111/ejh.13426. Epub 2020 May 29.
8
A simplified frailty scale predicts outcomes in transplant-ineligible patients with newly diagnosed multiple myeloma treated in the FIRST (MM-020) trial.
Leukemia. 2020 Jan;34(1):224-233. doi: 10.1038/s41375-019-0539-0. Epub 2019 Aug 19.
Zotero 插件